Literature DB >> 30926273

Extent and Predictors of Potentially Inappropriate Antidepressant Use Among Older Adults With Dementia and Major Depressive Disorder.

Sandipan Bhattacharjee1, Jeannie K Lee2, Asad E Patanwala3, Nina Vadiei2, Daniel C Malone2, Shannon M Knapp4, Wei-Hsuan Lo-Ciganic5, William J Burke6.   

Abstract

OBJECTIVE: To quantify the extent and identify predictors of potentially inappropriate antidepressant use among older adults with dementia and newly diagnosed major depressive disorders (MDD).
METHODS: This retrospective cohort study included older adults (aged ≥65 years) with dementia and newly diagnosed MDD using Medicare 5% sample claims data (2012-2013). Based on Healthcare Effectiveness Data and Information Set guidelines, intake period for new antidepressant medication use was from May 1, 2012, through April 30, 2013. Index prescription start date was the first date of antidepressant prescription claim during the intake period. Dependent variable of this study was potentially inappropriate antidepressant use as defined by the Beers Criteria and the Screening Tool of Older Persons' potentially inappropriate Prescriptions criteria. The authors conducted multiple logistic regression analysis to identify individual-level predictors of potentially inappropriate antidepressant use.
RESULTS: The authors' final study sample consisted of 7,625 older adults with dementia and newly diagnosed MDD, among which 7.59% (N = 579) initiated treatment with a potentially inappropriate antidepressant. Paroxetine (N = 394) was the most commonly initiated potentially inappropriate antidepressant followed by amitriptyline (N = 104), nortriptyline (N = 35), and doxepin (N = 32). Initiation of a potentially inappropriate antidepressant was associated with age and baseline use of anxiolytic medications.
CONCLUSION: More than 7% of older adults in the study sample initiated a potentially inappropriate antidepressant, and the authors identified a few individual-level factors significantly associated with it. Appropriately tailored interventions to address modifiable and nonmodifiable factors significantly associated with potentially inappropriate antidepressant prescribing are required to minimize risks in this vulnerable population.
Copyright © 2019 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Beers Criteria; Dementia; Screening Tool of Older Persons’ potentially inappropriate Prescriptions criteria; antidepressants; depression; psychotherapy

Year:  2019        PMID: 30926273      PMCID: PMC6646083          DOI: 10.1016/j.jagp.2019.02.002

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  40 in total

Review 1.  Pharmacology of antidepressants.

Authors:  E Richelson
Journal:  Mayo Clin Proc       Date:  2001-05       Impact factor: 7.616

2.  Diffusion of new generation antidepressant treatment among elderly diagnosed with depression.

Authors:  Usha Sambamoorthi; Mark Olfson; James T Walkup; Stephen Crystal
Journal:  Med Care       Date:  2003-01       Impact factor: 2.983

3.  SSRI Antidepressant Medications: Adverse Effects and Tolerability.

Authors:  James M. Ferguson
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-02

Review 4.  Tricyclic antidepressant overdose: a review.

Authors:  G W Kerr; A C McGuffie; S Wilkie
Journal:  Emerg Med J       Date:  2001-07       Impact factor: 2.740

5.  Rates of clinical depression diagnosis, functional impairment, and nursing home placement in coexisting dementia and depression.

Authors:  Helen C Kales; Peijun Chen; Frederic C Blow; Deborah E Welsh; Alan M Mellow
Journal:  Am J Geriatr Psychiatry       Date:  2005-06       Impact factor: 4.105

6.  Use of psychotherapy for depression in older adults.

Authors:  Wenhui Wei; Usha Sambamoorthi; Mark Olfson; James T Walkup; Stephen Crystal
Journal:  Am J Psychiatry       Date:  2005-04       Impact factor: 18.112

7.  Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.

Authors:  J P Feighner; K Overø
Journal:  J Clin Psychiatry       Date:  1999-12       Impact factor: 4.384

8.  Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.

Authors:  Ellen M Whyte; James Basinski; Panthea Farhi; Mary Amanda Dew; Amy Begley; Benoit H Mulsant; Charles F Reynolds
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

9.  Diagnosis and treatment of depression in the elderly medicare population: predictors, disparities, and trends.

Authors:  Stephen Crystal; Usha Sambamoorthi; James T Walkup; Ayşe Akincigil
Journal:  J Am Geriatr Soc       Date:  2003-12       Impact factor: 5.562

10.  High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population.

Authors:  Adriana Perez; Monica Anzaldua; Joseph McCormick; Susan Fisher-Hoch
Journal:  J Gastroenterol Hepatol       Date:  2004-03       Impact factor: 4.029

View more
  3 in total

1.  Extent and Factors Associated with Adherence to Antidepressant Treatment During Acute and Continuation Phase Depression Treatment Among Older Adults with Dementia and Major Depressive Disorder.

Authors:  Sandipan Bhattacharjee; Jeannie K Lee; Nina Vadiei; Asad E Patanwala; Daniel C Malone; Shannon M Knapp; Wei-Hsuan Lo-Ciganic; William J Burke
Journal:  Neuropsychiatr Dis Treat       Date:  2020-06-08       Impact factor: 2.570

2.  Mindfulness-based cognitive therapy for depression in people with dementia: A qualitative study on participant, carer and facilitator experiences.

Authors:  Sarah Douglas; Josh Stott; Aimee Spector; Janina Brede; Éanna Hanratty; Georgina Charlesworth; Deirdre Noone; Jacob Payne; Mina Patel; Elisa Aguirre
Journal:  Dementia (London)       Date:  2021-09-24

3.  Evaluation of psychotropic medications use among elderly with psychiatric disorders in Saudi Arabia.

Authors:  Abdulkarim M Meraya; Otilia J F Banji; Moteb A Khobrani; Abdulaziz Alhossan
Journal:  Saudi Pharm J       Date:  2021-04-24       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.